Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., explained in plain language.
-
New hope for Hard-to-Treat colorectal cancer: targeted drug combo enters human trials
Disease control Not yet recruitingThis study tests a new drug called TQB2930, which targets the HER2 protein on cancer cells, combined with standard chemotherapy and possibly another drug (bevacizumab). The goal is to find the safest and most effective dose and see if it shrinks tumors in people with advanced col…
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: targeted drug TQB2102 enters phase 3 trial
Disease control Not yet recruitingThis Phase 3 trial tests a new drug called TQB2102, which delivers chemotherapy directly to HER2-positive cancer cells, in people with advanced colorectal cancer that has stopped responding to standard treatments. About 142 participants will be randomly assigned to receive either…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New pill aims to ease psoriatic arthritis pain
Disease control Not yet recruitingThis study tests a new drug called TQH3906 for people with active psoriatic arthritis, a condition causing joint pain and skin patches. About 156 adults will receive either TQH3906, a placebo, or an existing drug (tofacitinib) for 12 weeks. The main goal is to see if TQH3906 impr…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC